Janux Therapeutics JANX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $13.73M+37.3% | $10M0.0% | $10M+2,178% | $439K-95.3% | $9.34M-11.8% | ||
| $127.65M+1.4% | $125.9M+9.3% | $115.15M+16.2% | $99.14M+24.9% | $79.37M+16.1% | ||
| $43.06M+3.1% | $41.77M+6.7% | $39.13M-15.3% | $46.18M+6.0% | $43.55M+6.1% | ||
| $170.72M+1.8% | $167.67M+8.7% | $154.29M+6.2% | $145.32M+18.2% | $122.92M+12.3% | ||
| -$156.98M+0.4% | -$157.67M-9.3% | -$144.29M+0.4% | -$144.88M-27.6% | -$113.58M-14.9% | ||
| -1,143.1%+434pp | -1,576.7%-134pp | -1,442.9%+31,559pp | -33,002.1%-31,785pp | -1,216.6%-283pp | ||
| $42.51M-3.5% | $44.04M+3.9% | $42.39M+8.0% | $39.24M+9.5% | $35.84M+20.1% | ||
| $42.51M-3.5% | $44.04M+3.9% | $42.39M+8.0% | $39.24M+9.5% | $35.84M+20.1% | ||
| -$114.48M-0.8% | -$113.63M-11.5% | -$101.9M+3.5% | -$105.64M-35.9% | -$77.74M-12.7% | ||
| -833.6%+303pp | -1,136.3%-117pp | -1,019%+23,045pp | -24,064%-23,231pp | -832.7%-181pp | ||
| -$1.84-0.5% | -$1.83-9.6% | -$1.67+6.7% | -$1.79-32.6% | -$1.35-6.3% | ||
| -$1.84-0.5% | -$1.83-9.6% | -$1.67+6.7% | -$1.79-32.6% | -$1.35-6.3% | ||
| 248.6M+0.4% | 247.7M+3.4% | 239.5M+3.2% | 232.1M+3.3% | 224.6M+6.0% | ||
| 248.6M+0.4% | 247.7M+3.4% | 239.5M+3.2% | 232.1M+3.3% | 224.6M+6.0% | ||
| $42.51M-3.5% | $44.04M+3.9% | $42.39M+8.0% | $39.24M+9.5% | $35.84M+20.1% | ||
| -$156.98M+0.4% | -$157.67M-9.3% | -$144.29M+0.4% | -$144.88M-27.6% | -$113.58M-14.9% | ||
| -$155M+0.4% | -$155.64M-9.4% | -$142.22M+0.4% | -$142.8M-28.0% | -$111.54M-15.2% | ||
| -$155M+0.4% | -$155.64M-9.4% | -$142.22M+0.4% | -$142.8M-28.0% | -$111.54M-15.2% | ||
| -1,128.7%+428pp | -1,556.4%-134pp | -1,422.2%+31,106pp | -32,527.8%-31,333pp | -1,194.7%-281pp | ||
| -$156.98M+0.4% | -$157.67M-9.3% | -$144.29M+0.4% | -$144.88M-27.6% | -$113.58M-14.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Janux Therapeutics's revenue?
- Janux Therapeutics (JANX) generated $13.7M in revenue over the trailing twelve months, up 47.1% year over year.
- Is Janux Therapeutics profitable?
- Janux Therapeutics is not currently profitable: it reported a net loss of $114.5M over the trailing twelve months, a -833.6% net margin.
- What is Janux Therapeutics's earnings per share?
- Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.84.
- Where does Janux Therapeutics's income statement data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
